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1. INTRODUCTION {#dom13280-sec-0001}
===============

Sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors exert a variety of favourable glycaemic and extra‐glycaemic effects[1](#dom13280-bib-0001){ref-type="ref"}; in phase III randomized controlled trials (RCTs), SGLT2 inhibitors lowered glycated haemoglobin (HbA1c) concentration by \~0.5% to 0.7%, body weight by 2 to 3 kg, and blood pressure by 3 to 4 mm Hg in people with type 2 diabetes (T2D).[2](#dom13280-bib-0002){ref-type="ref"}, [3](#dom13280-bib-0003){ref-type="ref"} Although RCTs deliver the best evidence for clinical decisions, they have limited external transferability.[4](#dom13280-bib-0004){ref-type="ref"} Real‐world retrospective studies using routinely accumulated clinical data are regaining interest for their ability to collect large representative datasets in a relatively short time. These studies are subject to channelling bias (or confounding by indication),[5](#dom13280-bib-0005){ref-type="ref"} especially for newly marketed drugs.[6](#dom13280-bib-0006){ref-type="ref"} This can be addressed using strategies of propensity score matching (PSM).[7](#dom13280-bib-0007){ref-type="ref"} When a sufficient overlap between patient groups exists,[8](#dom13280-bib-0008){ref-type="ref"} PSM can generate quasi‐experimental comparisons that make retrospective studies closer to RCTs. For instance, 2 RCTs indicate that SGLT2 inhibitors improve cardiovascular outcomes in patients with T2D and high risk for or established cardiovascular disease[9](#dom13280-bib-0009){ref-type="ref"}, [10](#dom13280-bib-0010){ref-type="ref"} and 2 retrospective studies on administrative databases have confirmed these findings in broader T2D patient populations.[11](#dom13280-bib-0011){ref-type="ref"}, [12](#dom13280-bib-0012){ref-type="ref"}

The DARWIN‐T2D study was a multicentre Italian retrospective study, designed to evaluate the use and effectiveness of dapagliflozin, the first‐in‐class SGLT2 inhibitor in Italy, compared with other glucose‐lowering medications (GLMs) in routine clinical practice.[13](#dom13280-bib-0013){ref-type="ref"} In the present study, we report data on baseline clinical characteristics with their temporal trends, along with an initial assessment of effectiveness.

2. MATERIALS AND METHODS {#dom13280-sec-0002}
========================

We have previously published a detailed description of the design of the present study[13](#dom13280-bib-0013){ref-type="ref"} and an expanded Methods section can be found in the Supporting Information. Briefly, the DARWIN‐T2D study was a multicentre nationwide retrospective study, designed to evaluate the baseline clinical characteristics and the change in glycaemic and extra‐glycaemic effectiveness variables in patients initiated on dapagliflozin vs patients initiated on dipeptidyl peptidase‐4 (DPP‐4) inhibitors, gliclazide, or glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), in Italian diabetes outpatient clinics. The study flowchart is shown in Figure S1 in Appendix [S1](#dom13280-supitem-0001){ref-type="supplementary-material"}. Automated software retrospectively extracted data from the same electronic chart system at all centres.

2.1. Statistical analysis {#dom13280-sec-0003}
-------------------------

Continuous variables are presented as mean ± SD, and categorical variables are expressed as percentages. Normality was checked using the Kolmogorov--Smirnov test and non‐normal variables were log‐transformed. Comparison between the 2 groups was performed using the two‐tailed unpaired Student\'s *t* test or χ^2^ test. Adjusting for multiple testing was performed using the Benjamini--Hochberg procedure. The two‐tailed paired Student\'s *t* test was used to compare data collected at follow‐up with those collected at baseline. *P* values \<.05 were taken to indicate statistical significance.

3. RESULTS {#dom13280-sec-0004}
==========

3.1. Baseline clinical characteristics {#dom13280-sec-0005}
--------------------------------------

The study collected data from 46 Italian diabetes specialist outpatient clinics, for a total background population of 281 217 patients with T2D. For the purpose of the present analysis, we extracted detailed information on 17 285 patients who initiated dapagliflozin (*n* = 2484), a DPP‐4 inhibitor (*n* = 6594: sitagliptin 57.2%; alogliptin 19.7%; vildagliptin 19.6%; saxagliptin 3.5%), gliclazide (*n* = 5960), or a long‐acting GLP‐1RA (*n* = 2247: liraglutide 73.3%; exenatide extended release 26.7%) between March 15, 2015 and December 31, 2016.

The baseline clinical characteristics of patients in the 4 groups are shown in Table S1 in Appendix [S1](#dom13280-supitem-0001){ref-type="supplementary-material"}. Significant differences among groups were detected for most variables: patients initiated on dapagliflozin were younger, had longer diabetes duration and higher fasting plasma glucose level, HbA1c level and blood pressure than patients in the other 3 groups and were more obese than patients initiated on DPP‐4 inhibitors or gliclazide, but less obese than patients initiated on a GLP‐1RA. The baseline lipid profile was slightly but significantly worse in the dapagliflozin vs the DPP‐4 inhibitor and gliclazide groups, but not when compared with the GLP‐1RA group. The frequency of microangiopathy at baseline was higher in patients initiated on dapagliflozin than in the other 3 groups, whereas the frequency of macroangiopathy was lower in the dapagliflozin than in the DPP‐4 inhibitor and gliclazide groups.

Metformin and insulin use were more common in the dapagliflozin group than in the other 3 groups, at the time of prescription of the new drugs and in the previous prescription. More than half of patients receiving dapagliflozin were insulin‐treated, about half of whom were on basal‐bolus insulin. The historical therapeutic regimen was also more complex in the dapagliflozin than in the other groups. All concomitant cardiovascular medications were less frequent among dapagliflozin users than in the control groups.

Heterogeneity arising from the centre effect, geographical location, and temporal trends are described in the Supporting Information (Table S2, S3, Figures S2, S3 in Appendix [S1](#dom13280-supitem-0001){ref-type="supplementary-material"}).

3.2. Analyses of effectiveness {#dom13280-sec-0006}
------------------------------

Changes in glycaemic and extra‐glycaemic effectiveness variables were calculated for patients having a follow‐up visit 3 to 12 months after baseline and still being on drug. Of the 17 285 patients evaluated at baseline, *n* = 6751 (39.1%) had a follow‐up visit: *n* = 830 (33.4%) for dapagliflozin, *n* = 2999 (45.5%) for DPP‐4 inhibitors, *n* = 2111 (35.4%) for gliclazide, and *n* = 811 (36.1%) for GLP‐1RAs (Table [1](#dom13280-tbl-0001){ref-type="table"}, Figure [1](#dom13280-fig-0001){ref-type="fig"}).

###### 

Change in glycaemic and extra‐glycaemic effectiveness variables in the 4 groups

                             Dapagliflozin   DPP‐4 inhibitors                                                                                                
  -------------------------- --------------- ------------------ --------------- --------------- -------- ------ -------------- -------------- -------------- --------
  Age, years                 830             60.2 ± 9.3                                                  2999   67.2 ± 9.1                                   
  Sex male %                 830             61.2                                                        2999   59.3                                         
  BMI, kg/mq                 748             33.1 ± 6.0                                                  2644   29.1 ± 4.9                                   
  Duration, years            830             12.4 ± 8.2                                                  2999   11.0 ± 7.7                                   
  Follow‐up, days            830             168.1 ± 55.5                                                2999   185.7 ± 49.0                                 
  Weight, kg                 735             92.8 ± 19.0        90.1 ± 18.8     −2.7 ± 3.5      \<.001   2420   79.7 ± 15.2    79.2 ± 15.0    −0.5 ± 3.1     \<.001
  SBP, mm Hg                 513             138.6 ± 18.0       135.7 ± 17.1    −3.0 ± 17.7     \<.001   1702   136.3 ± 18.0   135.6 ± 17.7   −0.7 ± 19.6    .122
  DBP, mm Hg                 512             80.4 ± 10.3        79.1 ± 9.2      −1.3 ± 9.9      .004     1701   78.3 ± 9.1     78.0 ± 9.0     −0.3 ± 10.3    .293
  FPG, mg/dL                 616             174.7 ± 53.3       146.6 ± 45.0    −28.2 ± 54.5    \<.001   2004   153.4 ± 37.1   141.9 ± 34.1   −11.5 ± 39.9   \<.001
  HbA1c, %                   751             8.6 ± 1.4          7.9 ± 1.3       −0.7 ± 1.2      \<.001   2531   7.8 ± 0.9      7.1 ± 0.9      −0.6 ± 1.0     \<.001
  Total cholesterol, mg/dL   426             175.1 ± 40.6       171.6 ± 40.6    −3.5 ± 34.7     .039     1361   171.5 ± 35.7   166.1 ± 34.8   −5.4 ± 29.8    \<.001
  HDL cholesterol, mg/dL     409             45.9 ± 13.8        47.6 ± 13.2     1.6 ± 8.1       \<.001   1293   48.9 ± 13.9    49.2 ± 13.6    0.3 ± 7.9      .235
  TG, mg/dL                  420             171.0 ± 134.1      155.0 ± 113.4   −15.9 ± 135.4   .016     1325   142.2 ± 84.3   134.1 ± 72.3   −8.1 ± 70.3    \<.001
  LDL cholesterol, mg/dL     387             95.3 ± 32.8        93.3 ± 33.4     −2.0 ± 27.1     .147     1238   94.4 ± 31.0    90.2 ± 30.3    −4.2 ± 26.7    \<.001

                             Gliclazide   GLP‐1RA                                                                                                      
  -------------------------- ------------ --------------- -------------- -------------- -------- ----- --------------- --------------- --------------- --------
  Age, years                 2111         67.5 ± 9.2                                             811   61.7 ± 9.1                                      
  Sex male %                 2111         59.0                                                   811   54.1                                            
  BMI, kg/mq                 1851         29.8 ± 5.1                                             736   35.2 ± 5.7                                      
  Duration, years            2111         11.7 ± 7.5                                             811   10.0 ± 7.1                                      
  Follow‐up, days            2111         185.4 ± 59.4                                           811   168.8 ± 52.3                                    
  Weight, kg                 1741         82.1 ± 16.0     82.1 ± 15.9    −0.1 ± 3.2     .393     685   97.9 ± 17.9     95.5 ± 18.0     −2.4 ± 4.0      \<.001
  SBP, mm Hg                 1390         139.5 ± 19.6    139.6 ± 19.2   0.1 ± 19.2     .894     386   140.2 ± 18.7    138.8 ± 16.8    −1.4 ± 18.6     .138
  DBP, mm Hg                 1389         78.7 ± 9.6      78.3 ± 9.1     −0.3 ± 10.0    .206     386   80.7 ± 9.6      81.0 ± 9.7      0.3 ± 10.7      .556
  FPG, mg/dL                 1439         166.5 ± 44.8    151.7 ± 39.6   −14.8 ± 49.6   \<.001   473   156.4 ± 35.6    139.2 ± 36.3    −1‐7.2 ± 40.9   \<.001
  HbA1c, %                   1710         8.1 ± 1.2       7.5 ± 1.1      −0.6 ± 1.3     \<.001   688   7.8 ± 0.8       7.1 ± 0.9       −0.6 ± 1.0      \<.001
  Total cholesterol, mg/dL   868          173.6 ± 39.8    165.6 ± 37.0   −8.0 ± 31.3    \<.001   332   175.1 ± 43.1    163.5 ± 39.6    −11.6 ± 35.8    \<.001
  HDL cholesterol, mg/dL     826          47.4 ± 13.3     47.4 ± 12.9    0.0 ± 7.6      1.000    318   45.2 ± 11.4     45.6 ± 11.7     0.4 ± 7.0       .255
  TG, mg/dL                  843          155.1 ± 104.7   142.2 ± 78.3   −12.9 ± 83.2   \<.001   336   174.0 ± 112.5   165.0 ± 102.8   −8.9 ± 105.4    .121
  LDL cholesterol, mg/dL     785          95.7 ± 33.6     90.2 ± 31.8    −5.5 ± 26.4    \<.001   308   95.1 ± 35.2     85.0 ± 35.4     −10.1 ± 32.3    \<.001

Abbreviations: DBP, diastolic blood pressure; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; SBP, systolic blood pressure; TG, triglycerides.

For each treatment group and for each variable, the number of patients with available data in both the baseline and follow‐up visit are reported. Values are mean ± SD.

![Within‐group analysis of effectiveness. For A, glycated haemoglogin (HbA1c), B, body weight and C, systolic blood pressure, panels show baseline and follow‐up values, along with changes from baseline (right panels). Numbers on top of columns indicate the corresponding values. Numbers between brackets indicates the number of available measures for each outcome. \**P* \< .05 vs baseline. DPP‐4i, dipeptidyl peptidase‐4 inhibitor; Dapa, dapagliflozin; GLP‐1RA, glucagon‐like peptide‐1 receptor agonist; SBP, systolic blood pressure](DOM-20-1781-g001){#dom13280-fig-0001}

Patients initiated on dapagliflozin, after an average of 168 days (5.5 months), showed significant improvements in fasting plasma glucose (−28.2 mg/dL), HbA1c (−0.7%), body weight (−2.7 kg), systolic blood pressure (−3.0 mm Hg), diastolic blood pressure (−1.3 mm Hg), total cholesterol (−3.5 mg/dL), HDL cholesterol (+1.6 mg/dL) and triglycerides (−15.9 mg/dL), with no change in LDL cholesterol. For patients initiating dapagliflozin on a background of insulin therapy, HbA1c significantly declined by 0.8% (from 9.1% to 8.3%) and body weight significantly declined by 2.2 kg (from 93.2 to 91.0 kg).

Patients initiated on a DPP‐4 inhibitor, after an average 185 days (6.1 months), showed significant improvements in fasting plasma glucose (−11.5 mg/dL), HbA1c (−0.6%), body weight (−0.5 kg), total cholesterol (−5.4 mg/dL), triglycerides (−8.1 mg/dL) and LDL cholesterol (−4.2 mg/dL).

Patients initiated on gliclazide, after an average of 185 days (6.1 months), showed significant improvements in fasting plasma glucose (−14.8 mg/dL), HbA1c (−0.6%), total cholesterol (−8.0 mg/dL), triglyceride (−12.9 mg/dL) and LDL cholesterol (−5.5 mg/dL).

Patients initiated on a GLP‐1RA, after an average of 169 days (5.6 months), showed significant improvements in fasting plasma glucose (−17.2 mg/dL), HbA1c (−0.6%), body weight (−2.4 kg), total cholesterol (−11.6 mg/dL) and LDL cholesterol (−10.1 mg/dL).

The percentage of patients meeting the composite endpoint of simultaneous HbA1c and body weight reduction was 56.9% for dapagliflozin, 40.5% for DPP‐4 inhibitors, 28.7% for gliclazide, and 56.2% for GLP‐1RAs (Figure S4 in Appendix [S1](#dom13280-supitem-0001){ref-type="supplementary-material"}). The corresponding percentages for the combined endpoint of simultaneous HbA1c, body weight and SBP reductions were 31.5%, 18.2%, 12.3% and 29.7%, respectively.

For each group, we estimated the expected improvement in cardiovascular risk using the UK Prospective Diabetes Study risk engine.[14](#dom13280-bib-0014){ref-type="ref"} Patients initiated on dapagliflozin showed the most consistent and significant reduction in the estimated 10‐year risk of coronary heart disease, fatal coronary heart disease, stroke and fatal stroke (Table S4 in Appendix [S1](#dom13280-supitem-0001){ref-type="supplementary-material"}).

Results of PSM are described in the Supporting Information. Common support between the dapagliflozin and comparator groups was very low (Figure S5 in Appendix [S1](#dom13280-supitem-0001){ref-type="supplementary-material"}) and the conditions for comparing matched cohorts were precarious (Figure S6 in Appendix [S1](#dom13280-supitem-0001){ref-type="supplementary-material"}); therefore, outcome analysis after PSM was not performed.

4. DISCUSSION {#dom13280-sec-0007}
=============

The DARWIN‐T2D study was a large retrospective study using clinical data routinely accumulated in electronic charts, involving 17 285 patients, of whom 6751 underwent a follow‐up examination. The comparison of baseline characteristics showed statistically significant and clinically meaningful differences in most variables between patients who started dapagliflozin and those who started a comparator. This was expected from an individualized therapy approach, but the HbA1c divide among groups was striking. A baseline HbA1c value of 8.7% reflects that dapagliflozin was being preferentially used in patients with moderately to severely uncontrolled diabetes. The reason for this channelling is probably 2‐fold. First, incretin‐based therapies were reimbursed by the Italian Healthcare System only if initiated in patients with an HbA1c between 7.5% and 9.0%, whereas such a limitation was not imposed on SGLT2 inhibitors. Dapagliflozin was reimbursed only in association with metformin and/or insulin (including the basal‐bolus regimen), whereas incretin‐based therapies could be reimbursed with multiple combinations of GLMs but not with basal‐bolus insulin, and gliclazide had no reimbursement limitations. These different criteria were responsible for enriching insulin therapy among patients initiating dapagliflozin. The high baseline HbA1c and the more frequent use of previous GLMs suggests that many patients initiating dapagliflozin were poor responders to other GLM classes. Second, newly marketed drugs are initially tested on the most difficult‐to‐treat patients, whereas the peculiar characteristics of patients initiating a new drug are expected to mitigate over time when the new drug becomes more established. A time‐trend analysis showed that the overall differences in clinical characteristics at the time patients initiated dapagliflozin vs other treatments were tapering over time, indicating that dapagliflozin was being progressively used in less severe cases.

The analysis of effectiveness was based on 6751 patients still on drug at follow‐up, about 6 months after baseline. The within‐group analysis in the total cohort showed improvements in HbA1c (−0.7%), FPG (−28.2 mg/dL), body weight (−2.7 kg) and systolic blood pressure (−3.0 mm Hg) after initiation of dapagliflozin that were consistent with findings from phase III RCTs.[2](#dom13280-bib-0002){ref-type="ref"}, [3](#dom13280-bib-0003){ref-type="ref"} A benefit for lipid profile was also observed, confirming the increase in HDL cholesterol and reduction of triglycerides seen in RCTs,[15](#dom13280-bib-0015){ref-type="ref"} but with no significant increase in LDL cholesterol. Among patients initiating dapagliflozin on a background of insulin therapy, HbA1c and body weight declined more than in the corresponding RCTs.[16](#dom13280-bib-0016){ref-type="ref"} Effectiveness in patients initiated on DPP‐4 inhibitors, gliclazide, or a GLP‐1RA was also well within the range expected from RCTs.[17](#dom13280-bib-0017){ref-type="ref"} Cardiovascular risk estimated using the UK Prospective Diabetes Study risk engine,[14](#dom13280-bib-0014){ref-type="ref"} improved with all treatments, but only dapagliflozin therapy was associated with a significant reduction in the projected risk of all the 4 endpoints, because of simultaneous improvements in glucose, body weight, blood pressure and lipids.

Between‐group comparisons of effectiveness were hampered by massive differences in baseline clinical characteristics that could not be overcome by PSM. Further analyses will be performed on the DARWIN‐T2D database and its follow‐up extension to provide more information on comparative effectiveness.

The present study has all the limitations inherent to its retrospective nature, including patient heterogeneity, risk of inverse causality, and concerns with regard to data quality and missingness. Importantly, the DARWIN‐T2D database is not yet linked with administrative registries and data on hard cardiovascular endpoints are not available. Major strengths of the DARWIN‐T2D study include the large sample size with nationwide distribution, the extensive patient characterization and, above all, the automatic data extraction from the same electronic chart, which granted uniform data coding and limited reporting errors.

In conclusion, during the first 21 months after marketing authorization approval in Italian routine clinical practice, dapagliflozin was prescribed to the most difficult‐to‐treat patients, many of whom were poor responders to previous GLMs and \> 50% were on insulin. A "launch effect" and differential reimbursement criteria were responsible for this massive channelling, but the scenario is progressively changing. Nonetheless, even in difficult‐to‐treat patients, the effectiveness of dapagliflozin with regard to glycaemic and extra‐glycaemic endpoints was similar to results obtained in RCTs and \> 50% of patients experienced a simultaneous reduction in HbA1c and body weight.

COMPOSITION OF THE DARWIN‐T2D DATABASE {#dom13280-sec-0008}
======================================
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